Stryker Corporation: Capital Budgeting Custom Case Solution & Analysis

1. Evidence Brief: Stryker Corporation Capital Budgeting

Financial Metrics

Operational Facts

• Structure: 12 decentralized divisions operating as independent profit centers. (Paragraph 4)
• Capital Approval: Division presidents historically held authority for most capital expenditures. (Paragraph 6)
• Geography: Global operations with significant manufacturing in Ireland and Michigan. (Exhibit 2)
• IT Infrastructure: Fragmented systems across divisions; lack of a unified data platform. (Paragraph 12)

Stakeholder Positions

• Stephen MacMillan (CEO): Advocates for increased discipline and enterprise-level coordination to sustain growth. (Paragraph 8)
• Dean Bergy (CFO): Focuses on financial rigor and standardized metrics for capital allocation. (Paragraph 10)
• Division Presidents: Prioritize autonomy and speed of execution; fear that centralization will slow down innovation. (Paragraph 14)

Information Gaps

• Specific Weighted Average Cost of Capital (WACC) applied to individual divisions versus the corporate hurdle rate.
• Detailed competitor capital expenditure benchmarks in the orthopedic and medical device sectors.
• Projected maintenance costs for the proposed ERP system beyond the initial implementation phase.

2. Strategic Analysis

Core Strategic Question

• How can Stryker transition its capital allocation process to support an integrated enterprise strategy without eroding the entrepreneurial speed that drove its historical 20 percent growth?
• Which of the four major capital projects should receive funding given the current constraints on management attention and financial targets?

Structural Analysis

Agency Theory and Resource Allocation: The current decentralized model creates a classic agency problem. Division presidents optimize for local results—often short-term—which may lead to sub-optimal capital allocation at the corporate level. The lack of a common IT language (ERP) prevents the CFO from having a clear view of cross-divisional efficiencies.

Capital Rationing Framework: Stryker is not constrained by cash but by its 20 percent EPS growth commitment. Every capital project must be evaluated against its ability to contribute to this specific earnings target. High-IRR projects that require long gestation periods (like Biotech) threaten short-term EPS, while low-IRR infrastructure (ERP) is necessary for long-term survival.

Strategic Options

• Option 1: The Entrepreneurial Status Quo. Maintain full divisional autonomy.
  Rationale: Preserves the culture that delivered decades of growth.
  Trade-off: Risks inefficient duplication of assets and continued IT fragmentation.
• Option 2: Centralized Capital Committee. All projects over 5 million dollars require corporate approval based on standardized NPV/IRR.
  Rationale: Ensures capital flows to the highest-return opportunities.
  Trade-off: Increases bureaucracy and potentially alienates top divisional talent.
• Option 3: Strategic Tiered Allocation (Recommended). Categorize projects into Operational Excellence (Manufacturing), Growth (R and D), and Enterprise Infrastructure (ERP). Use different hurdle rates and approval paths for each.
  Rationale: Recognizes that an ERP system and a biotech venture cannot be judged by the same metrics.

Preliminary Recommendation

Stryker should adopt Option 3. Immediate priority must be given to the ERP system and the Instruments expansion. The ERP is the foundational requirement for any future integration benefits. The Instruments expansion provides the most certain short-term return to protect the 20 percent EPS target. The Biotech project should be deferred or restructured as a staged investment to mitigate risk to the quarterly earnings profile.

3. Operations and Implementation Planner

Critical Path

1. Month 1: Establish the Capital Review Committee (CRC) led by the CFO. Define three distinct investment tiers: Infrastructure, Core Expansion, and High-Risk Innovation.
2. Month 2-3: Approve the ERP project as a mandatory enterprise mandate. Funding will be shared across divisions to ensure buy-in.
3. Month 4: Standardize the business case template for all projects exceeding 10 million dollars, requiring explicit EPS impact modeling for the next 12 quarters.
4. Month 6: Initiate the Instruments manufacturing expansion to secure supply chain capacity for the following fiscal year.

Key Constraints

• Divisional Resistance: Division presidents may view centralized ERP as a loss of control over their data and processes.
• Execution Bandwidth: Implementing a 14 million dollar ERP while simultaneously expanding manufacturing facilities will strain the corporate engineering and IT teams.

Risk-Adjusted Implementation Strategy

The implementation will use a phased rollout for the ERP to avoid total system shock. Contingency funds of 15 percent should be added to the Biotech and ERP budgets to account for historical cost overruns in these categories. If EPS growth dips below 18 percent in any quarter, the Biotech (OP-1) spending will be slowed automatically to preserve the bottom line.

4. Executive Review and BLUF

BLUF

Stryker must evolve from a collection of independent businesses into an integrated enterprise. The current decentralized capital process is a liability that obscures systemic risks and prevents essential infrastructure investment. We recommend an immediate transition to a tiered capital approval framework. Priority must be given to the ERP system and Instruments expansion. This secures the operational foundation and short-term earnings while deferring high-volatility biotech spend. Approve the ERP and Instruments projects immediately; place Endoscopy and Biotech under a second-stage review.

Dangerous Assumption

The most dangerous assumption is that the decentralized culture can survive the transition to a unified ERP system. The analysis assumes that division presidents will cooperate with a central IT mandate that reduces their local autonomy. If they resist, the 14 million dollar ERP investment will fail to deliver the expected data transparency.

Unaddressed Risks

• Talent Attrition: High probability. Top-performing division presidents may leave for competitors if they feel their entrepreneurial authority is being curtailed by the new Capital Review Committee.
• Biotech Obsolescence: Moderate probability. Deferring or staging the OP-1 project may allow competitors to capture the market, rendering the 55 million dollar investment opportunity worthless in three years.

Unconsidered Alternative

The team did not consider a partial spin-off or tracking stock for the Biotech division. This would allow Stryker to fund the high-risk OP-1 project using external capital, thereby insulating the Stryker EPS from the heavy R and D drag while retaining long-term upside through a majority ownership stake.

Verdict: APPROVED FOR LEADERSHIP REVIEW